December 2, 2022
Taisho Pharmaceutical rolled out Nanozora (ozoralizumab), a TNFα inhibitor licensed from Belgium-based Ablynx, for the treatment of rheumatoid arthritis (RA) in Japan, making it the country’s first “nanobody” agent. Nanozora is a trivalent anti-TNFα nanobody compound that is composed of...read more